Learn About Can-Fite BioPharma (NYSE American: CANF) in Exclusive Investor Group Call
Tuesday, September 22, 2020 4:15 pm ET
Join Dr. Pnina Fishman, CEO of Can-Fite BioPharma (NYSE American: CANF) (TASE: CFBI), to learn how the biotechnology company is advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases.
Call information:
Tuesday, September 22, 2020, 4:15 pm ET
Conference Line: (866) 821-0302 (no password)*
*U.S. callers only. Callers from other countries can email victor@redchip.com for dial-in information from their country.
If you have any questions, or would like to learn more, contact me, Victor Roberts, at (407) 571-0909, or by email at Victor@redchip.com.
About Can-Fite BioPharma Ltd. (NYSE American: CANF)
Can-Fite BioPharma Ltd. (NYSE American: CANF) is an advanced clinical stage drug development company with a platform technology that addresses multi-billion-dollar markets in the treatment of autoimmune inflammatory diseases including Rheumatoid Arthritis and Psoriasis, and liver diseases including advanced liver cancer and NASH. CanFite’s drugs have an excellent safety profile with experience in over 1,000 patients. CanFite’s intellectual property portfolio consists of 13 patent families issued and pending. Piclidenoson and Namodenoson have been out-licensed in select territories with approximately $18 million received to date. Piclidenoson received approval for COVID-19 clinicial trial in Israel in April 2020 and is expected to file its IND in the US in the near-term.
Key Highlights:
-Advanced clinical stage drug development company with a compelling platform technology
-Small molecule drug products in Phase II and Phase III clinical studies; covered by 13 patent families issued and pending
-Developing cannabinoid-based treatments for cancer, inflammatory, autoimmune, and metabolic diseases
-Highly experienced management, clinical, and regulatory team
Successful corporate partnerships and licensing deals
